Literature DB >> 30070719

CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma.

Long-Zi Liu1, Zhao Zhang1, Bo-Hao Zheng1, Yang Shi2, Men Duan1, Li-Jie Ma1, Zhi-Chao Wang1, Liang-Qing Dong1, Ping-Ping Dong3, Jie-Yi Shi1, Shu Zhang1, Zhen-Bin Ding1, Ai-Wu Ke1, Ya Cao4, Xiao-Ming Zhang5, Ruibin Xi2, Jian Zhou1,6,7, Jia Fan1,6,7, Xiao-Ying Wang1, Qiang Gao1,7.   

Abstract

Chemokines play a key role in orchestrating the recruitment and positioning of myeloid cells within the tumor microenvironment. However, the tropism regulation and functions of these cells in hepatocellular carcinoma (HCC) are not completely understood. Herein, by scrutinizing the expression of all chemokines in HCC cell lines and tissues, we found that CCL15 was the most abundantly expressed chemokine in human HCC. Further analyses showed that CCL15 expression was regulated by genetic, epigenetic, and microenvironmental factors, and negatively correlated with patient clinical outcome. In addition to promoting tumor invasion in an autocrine manner, CCL15 specifically recruited CCR1+ cells toward HCC invasive margin, approximately 80% of which were CD14+ monocytes. Clinically, a high density of marginal CCR1+ CD14+ monocytes positively correlated with CCL15 expression and was an independent index for dismal survival. Functionally, these tumor-educated monocytes directly accelerated tumor invasion and metastasis through bursting various pro-tumor factors and activating signal transducer and activator of transcription 1/3, extracellular signal-regulated kinase 1/2, and v-akt murine thymoma viral oncogene homolog signaling in HCC cells. Meanwhile, tumor-derived CCR1+ CD14+ monocytes expressed significantly higher levels of programmed cell death-ligand 1, B7-H3, and T-cell immunoglobulin domain and mucin domain-3 that may lead to immune suppression. Transcriptome sequencing confirmed that tumor-infiltrating CCR1+ CD14+ monocytes were reprogrammed to upregulate immune checkpoints, immune tolerogenic metabolic enzymes (indoleamine and arginase), inflammatory/pro-angiogenic cytokines, matrix remodeling proteases, and inflammatory chemokines. Orthotopic animal models confirmed that CCL15-CCR1 axis forested an inflammatory microenvironment enriched with CCR1+ monocytes and led to increased metastatic potential of HCC cells.
Conclusion: A complex tumor-promoting inflammatory microenvironment was shaped by CCL15-CCR1 axis in human HCC. Blockade of CCL15-CCR1 axis in HCC could be an effective anticancer therapy.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2018        PMID: 30070719     DOI: 10.1002/hep.30134

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

Review 1.  Immunotherapies for hepatocellular carcinoma.

Authors:  Josep M Llovet; Florian Castet; Mathias Heikenwalder; Mala K Maini; Vincenzo Mazzaferro; David J Pinato; Eli Pikarsky; Andrew X Zhu; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2021-11-11       Impact factor: 65.011

Review 2.  Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.

Authors:  Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

3.  Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis.

Authors:  Zhijun Liu; Yuyu You; Qiyi Chen; Guobang Li; Wenfeng Pan; Qing Yang; Jiajun Dong; Yi Wu; Jin-Xin Bei; Chaoyun Pan; Fuming Li; Bo Li
Journal:  Mol Ther       Date:  2021-10-01       Impact factor: 11.454

Review 4.  Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.

Authors:  Pil Soo Sung
Journal:  Clin Mol Hepatol       Date:  2021-10-19

5.  IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.

Authors:  Wenjie Zhang; Yang Liu; Zhongyi Yan; Hui Yang; Wei Sun; Yongliang Yao; Yun Chen; Runqiu Jiang
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

6.  TIM-3 restrains anti-tumour immunity by regulating inflammasome activation.

Authors:  Karen O Dixon; Marcin Tabaka; Markus A Schramm; Sheng Xiao; Ruihan Tang; Danielle Dionne; Ana C Anderson; Orit Rozenblatt-Rosen; Aviv Regev; Vijay K Kuchroo
Journal:  Nature       Date:  2021-06-09       Impact factor: 49.962

Review 7.  Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.

Authors:  Tong Fu; Lei-Jie Dai; Song-Yang Wu; Yi Xiao; Ding Ma; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  J Hematol Oncol       Date:  2021-06-25       Impact factor: 17.388

8.  DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.

Authors:  Danjun Song; Yining Wang; Kai Zhu; Lingyu Tian; Qiang Gao; Jian Zhou; Jia Fan; Xiaoying Wang
Journal:  World J Surg Oncol       Date:  2020-07-20       Impact factor: 2.754

9.  Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE.

Authors:  Jun-Xiang Li; Peng-Fei Pang; Tian-Cheng Wang; Tian-Zhi An
Journal:  Risk Manag Healthc Policy       Date:  2021-06-21

10.  SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.

Authors:  Chenhao Zhou; Chunxiao Liu; Wenjie Liu; Wanyong Chen; Yirui Yin; Chia-Wei Li; Jennifer L Hsu; Jialei Sun; Qiang Zhou; Hui Li; Bo Hu; Peiyao Fu; Manar Atyah; Qianni Ma; Yang Xu; Qiongzhu Dong; Mien-Chie Hung; Ning Ren
Journal:  Theranostics       Date:  2020-03-25       Impact factor: 11.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.